SAFETY AND EFFICACY OF VANDETANIB AS SYSTEMIC TREATMENT FOR PATIENTS WITH ADVANCED AND PROGRESSIVE MEDULLARY THYROID CANCER (MTC)

被引：0

作者：

Grande, E. ^{[1
]}

Martinez-Trufero, J. ^{[2
]}

Arevalo, S. ^{[3
]}

Alvarez-Escola, C. ^{[4
]}

Beltran, M. ^{[5
]}

Jimenez Fonseca, P. ^{[6
]}

Alonso-Gordoa, T. ^{[1
]}

Dalmau, E. ^{[7
]}

Duran, M. ^{[8
]}

Gallegos, I. ^{[9
]}

Manzano, J. L. ^{[10
]}

Mesia, R. ^{[11
]}

Pajares, I. ^{[12
]}

Fuentes, J. ^{[13
]}

Grau, J. J. ^{[14
]}

Reig Torras, O. ^{[14
]}

Trigo, J. M. ^{[15
]}

Pelaez, B. ^{[16
]}

Zafon, C. ^{[17
]}

Capdevila, J. ^{[18
]}

机构：

[1] Ramon & Cajal Univ Hosp, Med Oncol Dept, Madrid, Spain

[2] HU Miguel Servet, Zaragoza, Spain

[3] Hosp Donostia, Med Oncol Dept, San Sebastian, Spain

[4] La Paz Univ Hosp, Dept Endocrinol, Madrid, Spain

[5] ICO Girona, Girona, Spain

[6] Hosp Univ Cent Asturias, Serv Oncol Med, Oviedo, Spain

[7] Corp Hosp Parc Tauli, Sabadell, Spain

[8] Hosp Rey Juan Carlos, Mostoles, Spain

[9] Hosp Gen Segovia, Serv Oncol Med, Segovia, Spain

[10] ICO Hosp Germans Trias & Pujol, Barcelona, Spain

[11] Inst Catala Oncol ICO Hosp, IDIBELL Head & Neck Canc Unit, Med Oncol Dept, Barcelona, Spain

[12] Hosp Clin Lozano Blesa, Zaragoza, Spain

[13] Hosp Valme, Seville, Spain

[14] Hosp Clin Barcelona, Barcelona, Spain

[15] Hosp Univ Virgen de la Victoria, Malaga, Spain

[16] Univ Hosptial Valladolid, Valladolid, Spain

[17] Vall de Hebron Univ Hosp, Endocrinol Dept, Barcelona, Spain

[18] Vall dHebron Univ Hosp, Barcelona, Spain

来源：

ANNALS OF ONCOLOGY | 2014年 / 25卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

1161P

引用

页数：1

共 50 条

[31] Vandetanib for the Treatment of Medullary Thyroid Carcinoma
Cooper, Maryann R.
Yi, Soo Yun
Alghamdi, Wael
Shaheen, Daniel J.
Steinberg, Michael
ANNALS OF PHARMACOTHERAPY, 2014, 48 (03) : 387 - 394
[32] Use of vandetanib in medullary thyroid cancer
Marquez Fernandez, E.
Marmesat Rodas, B.
Quesada Sanz, M. P.
Guerra Estevez, D.
Villanueva Jimenez, P.
INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2016, 38 (02) : 587 - 587
[33] VANDETANIB THERAPY IN MEDULLARY THYROID CANCER
Grabowski, P.
Briest, F.
Baum, R. P.
Zaknun, J. J.
Kulkarni, H. R.
Zeitz, M.
Hoersch, D.
DRUGS OF TODAY, 2012, 48 (11) : 723 - 733
[34] Vandetanib: opening a new treatment practice in advanced medullary thyroid carcinoma
Durante, Cosimo
Paciaroni, Alessandra
Plasmati, Katia
Trulli, Fabiana
Filetti, Sebastiano
ENDOCRINE, 2013, 44 (02) : 334 - 342
[35] Vandetanib (ZD6474) in the Treatment of Medullary Thyroid Cancer
Deshpande, Hari
Roman, Sanziana
Thumar, Jaykumar
Sosa, Julie Ann
CLINICAL MEDICINE INSIGHTS-ONCOLOGY, 2011, 5 : 213 - 221
[36] Vandetanib (Caprelsa) for Medullary Thyroid Cancer
不详
MEDICAL LETTER ON DRUGS AND THERAPEUTICS, 2012, 54 (1381): : 3 - 4
[37] Vandetanib: opening a new treatment practice in advanced medullary thyroid carcinoma
Cosimo Durante
Alessandra Paciaroni
Katia Plasmati
Fabiana Trulli
Sebastiano Filetti
Endocrine, 2013, 44 : 334 - 342
[38] Pazopanib, Cabozantinib, and Vandetanib in the Treatment of Progressive Medullary Thyroid Cancer with a Special Focus on the Adverse Effects on Hypertension
Milling, Rikke Vilsboll
Grimm, Daniela
Krueger, Marcus
Grosse, Jirka
Kopp, Sascha
Bauer, Johann
Infanger, Manfred
Wehland, Markus
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2018, 19 (10)
[39] Pretargeted radioimmunotherapy (pRAIT) in progressive medullary thyroid cancer (MTC)
Salaun, Pierre
Bournaud, Claire
Bardet, Stephane
Vuillez, Jean-Philippe
Taieb, David
Ansquer, Catherine
Barbet, Jacques
Goldenberg, David
Chatal, Jean-Francois
Kraeber-Bodere, Francoise
JOURNAL OF NUCLEAR MEDICINE, 2011, 52
[40] Vandetanib, in the management of patients with locally advanced or metastatic medullary thyroid carcinomas
Chougnet, Cecile N.
Schlumberger, Martin
Leboulleux, Sophie
Baudin, Eric
BULLETIN DU CANCER, 2014, 101 (09) : 891 - 895

← 1 2 3 4 5 →